PapersPMID:27912875
Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.
- findings
- 3
- compound
- 1
- endpoints
- 3
- Study, every finding
- RCT · 6 months
- Dose studied, every finding
- 1500 mg/day dry extract (500 mg capsule three times daily)
- Population, every finding
- adults with moderate-to-severe generalized anxiety disorder who responded to 12 weeks of open-label chamomile extract, then randomized to continue chamomile or switch to placebo for 26 weeks
What moved
How to read these marks →- Decreases body mass
moderate
“During the 26-week continuation phase, the chamomile group had a relatively lower weight than the placebo group (P = 0.046; Fig. 4).”
“The chamomile group also had significantly lower mean arterial blood pressure (P = 0.0063; Fig. 5) and systolic pressure (P = 0.0012), and had a non-significant trend toward lower diastolic pressure (P = 0.057).”
- Decreases mean arterial pressure
moderate
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Outpatients with moderate-to-severe generalized anxiety disorder who responded to 12 weeks of open-label chamomile extract, randomized to continuation chamomile or placebo
- Participants
- 93
- Comparator
- placebo
- Duration
- 182 days
- Endpoints measured
- 17